Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of advanced NSCLC. * Stage III with pleural effusion and stage IV. * Patients are 70 years old. * Patients with 1 \> ECOG PS =1. * Patients must have at least one measurable lesion, no previously irradiated. * Life expectancy of at least 12 weeks. * Adequate organ function according to the following criteria: * Bone marrow: ANC \>= 2.0x10(9)cells/L; Platelet count \>= 100x10(9)cells/L; Leukocyte count \>= 4000x10(6)/L; Hemoglobin \>= 10 g/dL. * Liver function: Bilirubin \<= 1.5 X ULN; Alkaline phosphatase \<= 5 x ULN;AST and ALT \<= 1.5 x ULN. * Renal function: serum creatinine \<= 2mg/dL. Exclusion Criteria: * Prior systemic chemotherapy for advanced disease. * Patients with symptomatic brain metastases. * No measurable bone metastases or malignant pleural effusion as only measurable lesion. * History of prior malignancies, except curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years. * History of hypersensitivity reaction to study drugs. * Concurrent treatment with other experimental drugs. * Current peripheral neuropathy NCI grade 2. * Participation in clinical trials within 30 days of study entry. * Major surgery, open biopsy or traumatic lesion 28 days before to study start.